Compare AbbVie Inc (ABBV) vs Lufax Holding Ltd (LU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Lufax Holding Ltd — how do they compare? AbbVie Inc trades at $253.95 (market cap $449.91B), while Lufax Holding Ltd trades at $1.39 (market cap $2.41B). The key difference: AbbVie Inc is far larger — about 186.7× Lufax Holding Ltd's market cap, and AbbVie Inc pays a 2.72% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals.
| ABBV | LU | |
|---|---|---|
Market Cap | $449.91B | $2.41B |
Sector | Health | Technology |
52-Week High | $261.07 | $4.40 |
52-Week Low | $184.85 | $1.23 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
LU trades at $1.42, up 1.43% today, with a bullish technical signal but bearish moving averages. The stock shows deep value with a P/S of 0.36 and P/B of 0.1, yet profitability is weak with a -9.08% net margin and negative ROE. Recent news is dominated by a securities class action lawsuit with a May 20, 2026 deadline, creating significant headline risk.
The outlook is mixed; low valuations and a bullish analyst consensus (61.5% buy ratings) suggest potential upside, but negative earnings, cash flow challenges, and legal overhang present substantial risks. Investor sentiment is cautious due to the litigation, making near-term performance highly dependent on case developments and future earnings delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
